TIBER CREEK GROUP for JAZZ PHARMACEUTICALS
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Issues related to the FDA and the STATES Act (S. 3032), HHS pertaining to CBD policy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| EMILY KIRLIN | — |
| MATTHEW LEFFINGWELL | — |
| TIMOTHY A MOLINO | — |
Health Issues HCR
Issues related to the FDA STATES Act (S. 3032), and Health and Human Services pertaining to CBD policies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| EMILY KIRLIN | — |
| MATTHEW LEFFINGWELL | — |
| TIMOTHY A MOLINO | — |
Budget/Appropriations BUD
Appropriations issues related to the FDA CBD products, HHS pertaining to CBD policy. Fiscal Year 2021 Labor/HHS Education funding bill (H.R. 7614), Ag/FDA Appropriations (H.R. 7610), Commerce, Justice, Science Appropriations (H.R. 7667). H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| EMILY KIRLIN | — |
| MATTHEW LEFFINGWELL | — |
| TIMOTHY A MOLINO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.